癌症仍然是全球健康挑战,需要不断改进诊断和治疗策略。本文综述了非侵入性生物标志物在癌症诊断和治疗中的应用。它们在早期检测中的作用,疾病监测,和个性化的治疗干预措施。通过对文献的系统回顾,我们确定了45项相关研究,突出了这些生物标志物在各种癌症类型中的潜力,如乳房,前列腺,肺,和大肠癌。讨论的非侵入性生物标志物包括液体活检,表观遗传标记,非编码RNA,外泌体货物,和代谢物。值得注意的是,液体活检,特别是那些基于循环肿瘤DNA(ctDNA)的,已经成为早期最有前途的方法,非侵入性癌症检测,因为它们能够从易于获取的血液样本中提供全面的遗传和表观遗传信息。这篇综述展示了非侵入性生物标志物如何促进早期癌症检测,准确的子分型,和量身定制的治疗策略,从而改善患者的预后。它强调了非侵入性生物标志物在肿瘤学中的转化潜力,强调它们在加强早期检测方面的应用,存活率,和癌症护理中的治疗精度。
■https://www.crd.约克。AC.uk/prospro/display_record.php?ID=CRD4202347474749PROSPERO,标识符CRD42023474749。
Cancer remains a global health challenge, necessitating continuous advancements in diagnostic and treatment strategies. This
review focuses on the utility of non-invasive biomarkers in cancer diagnosis and treatment, their role in early detection, disease monitoring, and personalized therapeutic interventions. Through a systematic
review of the literature, we identified 45 relevant studies that highlight the potential of these biomarkers across various cancer types, such as breast, prostate, lung, and colorectal cancers. The non-invasive biomarkers discussed include liquid biopsies, epigenetic markers, non-coding RNAs, exosomal cargo, and metabolites. Notably, liquid biopsies, particularly those based on circulating tumour DNA (ctDNA), have emerged as the most promising method for early, non-invasive cancer detection due to their ability to provide comprehensive genetic and epigenetic information from easily accessible blood samples. This
review demonstrates how non-invasive biomarkers can facilitate early cancer detection, accurate subtyping, and tailored treatment strategies, thereby improving patient outcomes. It underscores the transformative potential of non-invasive biomarkers in oncology, highlighting their application for enhancing early detection, survival rates, and treatment precision in cancer care.
UNASSIGNED: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023474749 PROSPERO, identifier CRD42023474749.